BRIEF-Bioxcel Therapeutics - As Of Nov 18, 431 Patent Has Been Accepted For Listing In FDA Approved Drug Products With Therapeutic Equivalence Evaluations

Reuters11-22

BRIEF-Bioxcel <a href="https://laohu8.com/S/LENZ">Therapeutics</a> - As Of Nov 18, 431 Patent Has Been Accepted For Listing In FDA Approved Drug Products With Therapeutic Equivalence Evaluations

Nov 21 (Reuters) - BioXcel Therapeutics Inc BTAI.O:

BIOXCEL THERAPEUTICS- AS OF NOV 18, 431 PATENT HAS BEEN ACCEPTED FOR LISTING IN FDA APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

Source text: [https://tinyurl.com/mt5xay6a]

Further company coverage: BTAI.O

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2485429586?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-22 05:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485429586","market":"us","top_or_hot":-1,"title":"BRIEF-Bioxcel Therapeutics - As Of Nov 18, 431 Patent Has Been Accepted For Listing In FDA Approved Drug Products With Therapeutic Equivalence Evaluations","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Bioxcel <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> - As Of Nov 18, 431 Patent Has Been Accepted For Listing In FDA Approved Drug Products With Therapeutic Equivalence Evaluations</title></head><body><p><span>Nov 21 (Reuters)</span><span> - </span>BioXcel Therapeutics Inc <span>BTAI.O</span>:</p><ul><li><p>BIOXCEL THERAPEUTICS- AS OF NOV 18, 431 PATENT HAS BEEN ACCEPTED FOR LISTING IN FDA APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS</p></li></ul><p>Source text: [https://tinyurl.com/mt5xay6a]</p><p>Further company coverage: <span>BTAI.O</span></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Bioxcel Therapeutics - As Of Nov 18, 431 Patent Has Been Accepted For Listing In FDA Approved Drug Products With Therapeutic Equivalence Evaluations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Bioxcel Therapeutics - As Of Nov 18, 431 Patent Has Been Accepted For Listing In FDA Approved Drug Products With Therapeutic Equivalence Evaluations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-22 05:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nFWN3MS11B:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Bioxcel Therapeutics - As Of Nov 18, 431 Patent Has Been Accepted For Listing In FDA Approved Drug Products With Therapeutic Equivalence EvaluationsNov 21 (Reuters) - BioXcel Therapeutics Inc ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nFWN3MS11B:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nFWN3MS11B:1","article_id":"2485429586","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485429586","pubTimestamp":1732226298,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Bioxcel Therapeutics - As Of Nov 18, 431 Patent Has Been Accepted For Listing In FDA Approved Drug Products With Therapeutic Equivalence EvaluationsNov 21 (Reuters) - BioXcel Therapeutics Inc BT","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BTAI":"Bioxcel Therapeutics Inc."},"translate_title":"简介-Bioxcel Therapeutics-截至11月18日，已有431项专利被接受列入FDA批准的具有治疗等效性评估的药品","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BTAI":0.9},"content_text":"BRIEF-Bioxcel Therapeutics - As Of Nov 18, 431 Patent Has Been Accepted For Listing In FDA Approved Drug Products With Therapeutic Equivalence EvaluationsNov 21 (Reuters) - BioXcel Therapeutics Inc BTAI.O:BIOXCEL THERAPEUTICS- AS OF NOV 18, 431 PATENT HAS BEEN ACCEPTED FOR LISTING IN FDA APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONSSource text: [https://tinyurl.com/mt5xay6a]Further company coverage: BTAI.O","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Policy And Regulatory","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485429586"}